Bionik Laboratories Corp. · OTC:BNKL
Bionik Laboratories — Investor Presentation (January 2019)
27 slides from Bionik Laboratories's investor presentation, Jan 7, 2019
Slide 1: Rehabilitation Therapy and Mobility Solutions 2019
REHABILITATION THERAPY AND MOBILITY SOLUTIONS 2019 Ticker: BNKL
Slide 2: Forward Looking Statements
This document is private and confidential, contains sensitive business information of Bionik Laboratories Corp . (“ Bionik ”) and is not for public distribution . This document has been prepared for informational purposes only and is provided personally to you . By accepting this document you agree
Slide 3: Bionik Laboratories: We Make Lives Better
Our artificial intelligence and machine learning technologies make rehabilitation methods and processes smarter and more intuitive for faster patient recovery. We design and manufacture products which connect to performance - based reimbursement programs for healthcare providers and institutions. We
Slide 4: Conventional therapy is not enough to help patients recover
CONVENTIONAL THERAPY IS NOT ENOUGH TO HELP PATIENTS RECOVER. There are 800,000 new U.S. stroke patients each year Eric Dusseux, CEO WE SERVICE AN ANNUAL $200 M MARKET OF HOSPITALS, CLINICS, INPATIENT REHABILITATION FACILITIES, AND SKILLED NURSING FACILITIES 4 Summary Health Statistics: National Heal
Slide 5: Targeting the home-based upper limb and walking assistance markets
WE ARE TARGETING THE ESTIMATED $ 2B MARKET FOR HOME - BASED, UPPER LIMB THERAPY …AND THE ESTIMATED $1B MARKET FOR WALKING ASSISTANCE DEVICES PRODUCTS UNDER DEVELOPMENT 5
Slide 6: Highlights
HIGHLIGHTS We Service the Growing Market Opportunity for New Rehabilitation Technology Strong demographics, plus new value - based reimbursement program requirements favor our technologies. BIONIK’s Platform Supports and Assists Insurance Reimbursement and Payments We meet the new outcome - based re
Slide 7: The Market, Its Trends, and a Trigger for Mass Adoption
THE MARKET, ITS TRENDS, AND A TRIGGER FOR MASS ADOPTION 7
Slide 8: The Rehabilitation Market
THE REHABILITATION MARKET ▪ The global rehabilitation equipment and devices market size was valued at $10.53 billion in 2016 and is expected to grow at a CAGR of 6.0% during 2018 - 2025 forecast period. (Grandview Research, 2017 ) ▪ The need for daily assistive devices for handicapped population aro
Slide 9: New Rules for Inpatient Rehabilitation Facilities and SNF Outcomes
New Rules for In - patient Rehabilitation Facilities (IRF) – October 2019 ▪ Rule favor Quality Indicators in the Patient Assessment Instrument (PAI) ▪ Quality indicator reporting on facility self - care and mobility scores will be made publicly available on IRF compare portion of CMS.gov for the fir
Slide 10: The Trigger for Mass Adoption
THE TRIGGER FOR MASS ADOPTION We beli eve we are uniquely positioned to take advantage of the trends and pending regulations in healthcare to supply hospitals, clinics and homes with advanced Evidence Based medical devices to improve neurological performance and produce the data that measures our pe
Slide 11: Our Team, Our Products and Competitive Landscape
OUR TEAM, OUR PRODUCTS AND COMPETITIVE LANDSCAPE ABOUT US 11
Slide 12: Management Team
MANAGEMENT TEAM Eric Dusseux, MD, MSc, MBA Chief Executive Officer Michal Prywata Co - Founder and CTO Leslie Markow, CPA, CA, CPA (Illinois) Chief Financial Officer Renaud Maloberti Chief Commercial Officer Former President of Europe and a director for Auregen BioTherapeutics Executive Committee Me
Slide 13: Board of Directors
BOARD OF DIRECTORS Eric Dusseux, MD, MSc, MBA Chief Executive Officer André Jacques Auberton - Hervé Chairman of the Board Rémi Gaston Dreyfus Director Peter Gerald Malone Independent Director Former President of Europe and a director for Auregen BioTherapeutics Executive Committee Member of Sanofi
Slide 14: The Science of Our Products
Robotic rehabilitation elicits brain neuroplasticity and recovery THE SCIENCE OF OUR PRODUCTS 14
Slide 15: Superior Outcomes vs. Conventional Rehabilitation
SUPERIOR OUTCOMES VS. CONVENTIONAL REHABILITATION: BETTER ASSET PRODUCTIVITY BIONIK’S ASSET PRODUCTIVITY CONVENTIONAL METHODS > Repetition of a few functional motor skills; habitual movements Superior Performance and Value vs. Conventional Rehabilitation BIONIK InMotion ™ > Reducing impairment; neur
Slide 16: Proven Effects on Brain Plasticity
PROVEN EFFECTS ON BRAIN PLASTICITY Data gathered from sample plots for a stroke patient at admission and after 14 and 70 days , following InMotion ™ ARM robotic therapy. Circle Evaluation Test Measures motor coordination, joint independence and motor planning Results: Improvements in acceleration, s
Slide 17: Our InMotion Product Line
OUR InMotion ™ PRODUCT LINE Motor therapy to help patients regain motor function following a neurological condition or injury . Provides patients with real - time Assistance - as - Needed™ while it gently assists where needed to help them complete various motor therapy activities ( 30 programs) . Th
Slide 18: Our Upper Limb Advantages
OUR UPPER LIMB ADVANTAGES 1 . Breath of Rehabilitation Offering BIONIK offers Arm, Hand and Wrist - most competitors have arm, only 2. Software / Artificial Intelligence Capability Broader measurement capability and greater adaptiveness through the patient session 3. Degree of Independent Clinical R
Slide 19: Growth Plans
Our Milestones Met and Our Market Opportunities GROWTH PLANS 19
Slide 20: We Hit Our Milestones
WE HIT OUR MILESTONES We have built a strong FOUNDATION OF CLINICAL PRODUCTS ▪ Well - positioned in healthcare robotics and artificial intelligence ▪ Developed systems with Key Opinion Leaders to enhance value proposition ▪ More than 65 peer - reviewed papers published, presenting clinical trials ;
Slide 21: We Are Optimized to Scale
▪ Commercial promise with next - generation products ▪ Directed towards hospitals and rehab centers, a new financial partner, a new sales force and a new strategy to rejuvenate sales ▪ Home - use rehabilitative products in development ▪ InMotionARM ™ at home in development ▪ A smart, lighter exoskel
Slide 22: Kindred Healthcare Contract
▪ Kindred Heathcare is a healthcare services company with revenues of approximately $3.3 Billion (Owned by Humana and private equity partners) ▪ First phase purchase agreement is for 21 Bionik InMotion Arm Robotic Systems ▪ Second phase will be broader deployment until at least end of 2022 across Ki
Slide 23: Installed hospital customers
Mercy Rehabilitation Hospital and Rehab Hospital, Des Moines, St. Louis, Springfield Franciscan Specialty Care, CHI Franciscan Rehabilitation Hospital Avon RH, University Hospital Avon Rehabilitation Hospital Lancaster Réhabilitation Hospital, Lancaster Réhabilitation Hospital NHS - CHC 1, Methodist
Slide 24: Financials
FINANCIALS BIONIK | 24
Slide 25: Summary Income Statement and Balance Sheet
Six Months ended September 30, 2018 Six Months ended September 30, 2017 Revenue 1,048,418 $309,367 Cost of Sales 637,236 89,125 Gross Profit 411,182 220,242 Operating Expenses 5,446,061 5,646,822 Other Expense (Income) (291,076) 429,297 Net Loss (4,743,803) (5,855,877) EPS (2.02) (8.84) SUMMARY INCO
Slide 26: Capitalization Table
CAPITALIZATION TABLE As of December 31, 2018 Common Shares Outstanding 2,611,538 1 Warrants 440,231 @ $44.21 WAEP 2 Options 185,603 @ $38.26 WAEP 2 Convertible Notes $3,150,000 aggregate principal amount 1 Includes 273,574 exchangeable shares 2 Weighted Average Exercise Price 26
Slide 27: Contact Us
Global Headquarters 483 Bay Street, Office N105 Toronto, ON M5G 2C9 Canada U.S. Headquarters 80 Coolidge Hill Road Watertown, MA 02472 United States CONTACT US www.bioniklabs.com 27
Bionik Laboratories — Investor Presentation (January 2019) on 6ix